


PATRONAGES - UNDER THE AUSPICES OF:



WITH THE UNCONDITIONED SUPPORT OF:

PLATINUM SPONSOR



GOLD SPONSOR



SILVER SPONSOR



GENERAL INFORMATION

VENUE

Hilton Milan
Via Luigi Galvani, 12, 20124 Milano

OFFICIAL LANGUAGE

The official language is English

OFFICIAL TIME

The official Time is Central European Summer Time (CEST), UTC +2

REGISTRATION

Registration is free of charge.
You may register for **IN-PERSON OR ONLINE-ONLY ACCESS**
<https://www.lungcancer-milan.com/>

C.M.E. CREDITS

C.M.E. for Italian participants only, for medical doctors (all disciplines), biologists, pharmacists, nurses.
In order to receive credits, participants must:
1. Attend at least 90% of the accredited CME program;
2. Complete online the CME test and the evaluation forms.
CME certificate will be sent by email at the end of the validation procedure (within 90 days).

ORGANIZING SECRETARIAT/CME PROVIDER



Events Congress&Communication provider 1023
Via Lotto,9 - 60019 Senigallia, Italy
Tel. +39 071 7930220
Fax. +39 071 7938406
segreteria@events-communication.com
www.events-communication.com



LUNG CANCER COCKTAIL WITH SCIENCE

2023
SEPTEMBER 25TH - MILAN, ITALY
& ONLINE

SCIENTIFIC PROGRAM

- 10:30** Registration
- 11:00** Welcome and Introduction
Giuseppe Lo Russo
Filippo de Braud

SESSION I NSCLC EARLY AND LOCALLY ADVANCED DISEASE

Chairs: **Laura Mazzeo, Sara Manglaviti**

- 11:10** Screening: from the literature to clinical practice
Ugo Pastorino
- 11:30** Adjuvant treatment in oncogene addicted and wt patients
Antonio Passaro
- 11:50** Neoadjuvant approach in oncogene addicted and wt patients
Tina Cascone

- 12:10** Not-resectable locally advanced disease
Benjamin Besse

- 12:30** Round Table and & Questions time
All

- 13:00** LUNCH

SESSION II NSCLC NON ONCOGENE ADDICTED ADVANCED DISEASE

Chairs: **Marta Brambilla, Teresa Beninato**

- 14:00** Old and New biomarkers for patients treated with ICIs
Paolo Bironzo

- 14:20** IO monotherapy and combo IO-IO
Andrea Ardizzoni

- 14:40** Combo IO-Chemo and IO-IO + Chemo
Marina Chiara Garassino

- 15:00** New agents and their role in the treatment of wt advanced NSCLC
Erminia Massarelli

- 15:20** Round Table and & Questions time
All

- 15:50** COFFEE BREAK

SESSION III NSCLC ONCOGENE ADDICTED ADVANCED DISEASE

Chairs: **Mario Occhipinti, Claudia Proto**

- 16:00** NGS and NSCLC: from tissue to blood
Francesco Grossi

- 16:20** EGFR common and uncommon Mutations: the present and the future
Luis Paz Ares

- 16:40** Current and future treatment algorithms for ALK, ROS1, RET and NTRK positive patients
Shirish Gadgeel

- 17:00** Updates for BRAF, MET, HER2 and KRAS positive patients
Enriqueta Felip

- 17:20** Round Table and & Questions time
All

SPECIAL LECTURES

Chairs: **Diego Signorelli, Giuseppe Viscardi**

- 17:50** New biomarkers for early diagnosis of lung cancer
Gabriella Sozzi

- 18:10** The role of Artificial Intelligence to improve treatment selection
Arsela Prelaj

- 18:30** Immunosenescence and biological hallmarks of ageing in the immunotherapy era
Roberto Ferrara

- 18:50** Conclusions remarks
Giuseppe Lo Russo

- 19:00** COCKTAIL

"Let's break the ice in lung cancer"



OVERVIEW

The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment.

PRESIDENT OF THE CONFERENCE

GIUSEPPE LO RUSSO
Thoracic Unit - Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

FACULTY

ARDIZZONI ANDREA Medical Oncology, University of Bologna, University Hospital S.Orsola-Malpighi, Bologna IT

BENINATO TERESA Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

BESSE BENJAMIN Medical Oncology Université Paris-Saclay, Clinical Research at Gustave Roussy Institut, Villejuif FR

BIRONZO PAOLO Dpt. of Oncology, University of Torino, IT

BRAMBILLA MARTA Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

CASCONE TINA Dpt. of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX USA

DE BRAUD FILIPPO Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

FELIP ENRIQUETA Lung Cancer Unit, Oncology Dpt., Vall d'Hebron University Hospital, Barcelona ES

FERRARA ROBERTO Thoracic Oncology and Molecular Immunology IRCCS Ospedale San Raffaele, Milano IT

GADGEEL SHIRISH Division of Hematology and Oncology, Dpt. of Internal Medicine, Henry Ford Cancer Institute, Detroit, MI USA

GARASSINO MARINA CHIARA Thoracic Oncology Program, University of Chicago, IL USA

GROSSI FRANCESCO Medical Oncology, University of Insubria, Ospedale di Circolo - ASST dei Sette Laghi Varese, IT

LO RUSSO GIUSEPPE Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

MANGLAVITI SARA Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

MASSARELLI ERMINIA Lung Cancer and Thoracic Oncology Program, Thoracic Oncology, Dpt. of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA USA

MAZZEO LAURA Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

OCCHIPINTI MARIO Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

PASSARO ANTONIO Thoracic Unit, IEO Istituto Europeo di Oncologia, Milano IT

PASTORINO UGO Thoracic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

PAZ ARES LUIS Medical Oncology Dpt, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid ES

PRELAJ ARSELA Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

PROTO CLAUDIA Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

SIGNORELLI DIEGO Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano IT

SOZZI GABRIELLA Tumor Genomics Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

VISCARDI GIUSEPPE Medical Oncology, Azienda Ospedaliera Monaldi Cotugno Cto, Università degli Studi della Campania Luigi Vanvitelli, Napoli IT